US · 21 CFR

Findings citing 21 CFR 211.94

Drug product containers and closures.

3 findings citing this section, drawn from 3 published documents. The most recent cases are below; the full set is in search.

Search all 21 CFR 211.94 findings

Recent findings

US FDA Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals 2025-03-11

Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).

See every finding in this document View official source
US FDA Sagent Pharmaceuticals, Inc. 2022-12-20

Your firm failed to ensure container closure systems provide protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product (21 CFR 211.94(b)).

See every finding in this document View official source
US FDA Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine 2021-11-16

Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).

See every finding in this document View official source

Terms related to this section

Section text

Other sections

These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Findings are extracted automatically from the regulator's published documents, and section citations are counted exactly as written in the source. “View official source” on each case links directly to that document.